Phase 2Recruiting
PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM
A Phase II Trial of PULSAR (Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy) Combined With PD-1 Ab and Chemotherapy Plus Bevacizumab for Colorectal Cancer Liver Metastasis
- Sponsor
- Fujian Cancer Hospital (Government)
- Enrolment
- 35 planned
- Conditions
- Colorectal Cancer Liver Metastasis
- Interventions
- Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy; Bevacizumab; Capecitabine; Oxaliplatin; Sintilimab
- Ages
- adults, older adults
- Registry
- NCT06788171
Full record on ClinicalTrials.gov
From the registry
To explore Progression-Free-Survival(FPS) of PULSAR(personalized ultrafractionated stereotactic adaptive radiotherapy) combined with PD-1 Ab and Chemotherapy plus Bevacizumabfor CRLM
Primary outcomes
- Progression-free-Survival
History
Primary completion expected
Last registry update
Started
Registered